Pharmaceutical manufacturing can lead to the contamination of water ways and supply. Here, the ultimate effects from pharma’s role in environmental pollution is examined.
List view / Grid view
Filter the results
During the manufacture of antibiotics, residues can contaminate the environment through wastewater, leading to antimicrobial resistance. However, a new government initiative in India aims to prevent this by regulating effluent.
The Project to Accelerate New Treatments for Tuberculosis (PAN-TB collaboration) was devised to create transformative regimens for TB treatment, irrespective of drug resistance status.
Researchers at Aston University and Birmingham Children’s Hospital, UK, have discovered a highly effective three-drug approach to treat Mycobacterium abscessus (M. abscessus), a notoriously drug-resistant pathogen that affects up to 13 percent of cystic fibrosis (CF) patients in the UK.
Research has developed bandages which change colour and release antibiotics and/or reactive oxygen species in response to an infected wound which could curb the spread of antibiotic resistance.
The World Health Organization (WHO) has released new reports which state that a lack of innovation in new antibiotic development is undermining efforts to combat drug-resistant infections.
A new report has said the majority of the active ingredients used in pharmaceuticals have never been evaluated for environmental risks.
The US FDA has granted approval for the marketing authorisation of Talicia, intended to treat adults with H. pylori infection.
The UK government will invest £3.5 million to help develop new antibitoic treatments for gonorrhoea and make them available to low- and middle-income countries.
The fight against antibiotic resistance could be improved with the discovery of a concept for fabricating nanomeshes as a drug delivery system.
Why has the pharma industry and its talents lost interest in developing new antibiotics?
The worldwide trade of the cephalosporin class of antibiotics will increase to $14.1 billion by the end of 2025.
The CMA alleges that a pharmaceutical company agreed to buy equal quantities of a pill from two drug suppliers, breaking competition law.
The NHS is set to launch a new payment method for antibiotic development to incentivise pharmaceutical companies.
According to Rutgers researchers, physicians are scaling back on prescribing antibiotics for long-term acne treatment in favour of a combination of therapies.